Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Pivonello, RosarioBancos, IrinaFeelders, Richard A.Kargi, Atil Y.Kerr, Janice M.Gordon, Murray B.Mariash, Cary N.Terzolo, MassimoEllison, NoelMoraitis, Andreas G.2023-06-262023-06-262022-04-27Pivonello R, Bancos I, Feelders RA, et al. Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Front Endocrinol (Lausanne). 2022;13:899616. Published 2022 Apr 27. doi:10.3389/fendo.2022.899616https://hdl.handle.net/1805/33972[This corrects the article DOI: 10.3389/fendo.2021.662865.].en-USAttribution 4.0 InternationalCushing syndromeClinical trialCortisolGlucocorticoidHypercortisolismHyperglycemiaHypertensionRelacorilantCorrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 StudyArticle